

**Name of the Issue: Fabino Life Sciences Limited (“Company” / “Issuer”)****Date of listing:** January 13, 2022

1. **Type of issue:** Initial Public Offer (IPO) of Fresh Issue on SME Platform of BSE Limited.
2. **Issue size:** Rs. 324.00 Lakhs  
*Source: Prospectus dated December 27, 2021.*
3. **Grade of issue along with name of the rating agency:** N.A.
4. **Subscription level:** 5.47 times  
*Source: Final post-issue monitoring report dated January 14, 2022.*
5. **QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges:**

- i. **Allotment in the issue:** Nil
- ii. **At the end of the 1<sup>st</sup> half year\* immediately after the listing of the issue (As on March 31, 2022):** Nil
- iii. **At the end of 1<sup>st</sup> FY(As on 31<sup>st</sup> March, 2022):** Nil
- iv. **At the end of 2<sup>nd</sup> FY(As on 31<sup>st</sup> March, 2023):** Nil
- v. **At the end of 3<sup>rd</sup> FY(As on 31<sup>st</sup> March, 2024):** Nil

\*Company’s shares are listed on SME Platform, Shareholding Pattern are disclosed on half-yearly basis.

Source: [www.bseindia.com](http://www.bseindia.com) (Shareholding Pattern)**6. Financials of the issuer:**

(Rs. in Lakhs)

Parameters	1 <sup>st</sup> FY	2 <sup>nd</sup> FY	3 <sup>rd</sup> FY
	2021-22	2022-23	2023-24
Income from operations (Net of Taxes)	420.06	336.01	608.41
Net Profit for the period	4.70	1.08	4.76
Paid-up equity share capital	210.00	210.00	210.00
Reserves excluding revaluation reserves	200.37	201.45	205.71

Source: Annual Reports of the Issuer.

**7. Trading status in the scrip of the issuer:**

Sr. No.	Particulars	Frequently Traded / Infrequently Traded
(i)	at the end of 1 <sup>st</sup> FY 2021-22	Frequently Traded
(ii)	at the end of 2 <sup>nd</sup> FY 2022- 23	Frequently Traded
(iii)	at the end of 3 <sup>rd</sup> FY 2023 -24	Frequently Traded

**8. Change, if any, in directors of issuer from the disclosures in the offer document:**

Sr. No.	Particulars	Name of Director	Ceased / Appointed
(i)	Directors as on Listing date	Atul Kumar Jain	-
		Aditya Mahavir Jain	-
		Arihant Jain	-
		Kuldeep Solanki	-
		Tesu Alakh	-
(ii)	at the end of 1 <sup>st</sup> FY 2021-22	-	-
(iii)	at the end of 2 <sup>nd</sup> FY 2022-23	Sumit Malik	Appointment as Non-Executive Director w.e.f. May 24, 2022
(iv)	at the end of 3 <sup>rd</sup> FY 2023-24	Satender Kumar Jain	Appointment as Executive Director w.e.f. December 26, 2023
		Atul Kumar Jain	Resignation as Managing Director w.e.f. December 26, 2023

Source: [www.bseindia.com](http://www.bseindia.com) (Corporate Announcements)**9. Status of implementation of project / commencement of commercial production:**

- (i) **As disclosed in the offer document** – During FY 2021-22
- (ii) **Actual Implementation** – During FY 2021-22
- (iii) **Reasons for delay in implementation, if any** – N.A.

10. Status of utilization of issue proceeds:

(i) As disclosed in the offer document –

(Rs. In Lakhs)

Sr. No.	Particulars	Amount to be Deployed	Actual implementation
1	Part Repayment of Loans	25.00	25.00
2	Funding Working capital requirements	204.90	204.90
3	General Corporate Purpose	50.44	50.44
	<b>Total</b>	<b>280.34</b>	<b>280.34</b>

(ii) Reasons for delay in implementation, if any –NA

11. Comments of monitoring agency, if applicable: N.A.

12. Price-related data Issue price: Rs. 36 per Equity Share

Price parameters	At close of listing day	At close of 30 <sup>th</sup> calendar day from listing day <sup>#</sup>	At close of 90 <sup>th</sup> calendar day from listing day <sup>#</sup>	As at the end of 1 <sup>st</sup> FY after the listing of the issue (31 <sup>st</sup> March, 2022)			As at the end of 2 <sup>nd</sup> FY after the listing of the issue (31 <sup>st</sup> March, 2023)			As at the end of 3 <sup>rd</sup> FY after the listing of the issue (31 <sup>st</sup> March, 2024)		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price <sup>7</sup>	High (during the FY) <sup>#</sup>	Low (during the FY) <sup>#</sup>
Market Price	40.35	35.45	26.00	27.25	48.95	23.90	33.00	37.95	22.50	39.57	43.84	27.80
Index (SENSEX)	61235.30	58152.92	58338.93	58568.51	62245.43	52260.82	58991.52	63583.07	50921.22	73651.35	74245.17	71674.42
SME IPO*	17433.79	16418.72	14458.96	13675.49	20510.33	6279.54	24110.49.	26366.28	11638.53	52725.41	59876.71	48667.72

<sup>#</sup> In the event any day falls on a holiday or if the stock was not traded on the said calendar days from the date of listing, the price / index of the immediate preceding trading day has been considered.

\*Since the Company is listed on SME platform of BSE, SME IPO is considered.

13. Basis for Issue Price and Comparison with Peer Group & Industry Average:

Accounting ratio	Name of Company	As disclosed in the offer document	At the end of 1 <sup>st</sup> FY 2021-22	At the end of 2 <sup>nd</sup> FY 2022-23	At the end of 3 <sup>rd</sup> FY 2023-24
EPS	<b>Issuer:</b> Fabino Life Sciences Limited	0.50	0.78	0.05	0.23
	<b>Peer Group:</b>				
	Earum Pharmaceuticals Limited	0.14	0.36	0.32	N.A.
	Vaishali Pharma Limited	0.99	3.82	6.26	0.68
	Chandra Bhagat Pharma Limited	0.25	1.06	1.2	2.03
	<b>Industry Avg:</b> Pharmaceuticals	N.A.	N.A.	N.A.	N.A.
P/E	<b>Issuer:</b> Fabino Life Sciences Limited	72	41.03	660	117.39
	<b>Peer Group:*</b>				
	Earum Pharmaceuticals Limited	492.85	3.19	6.59	N.A.
	Vaishali Pharma Limited	34.44	17.32	23.31	33.87
	Chandra Bhagat Pharma Limited	278	106.60	80.83	36.62
	<b>Industry Avg:</b> Pharmaceuticals	43.20	27.70	29.60	43.9
RoNW	<b>Issuer:</b> Fabino Life Sciences Limited	2.32%	1.15%	0.26%	0.01%
	<b>Peer Group:*</b>				
	Earum Pharmaceuticals Limited	0.61%	13.30%	10.60%	N.A.
	Vaishali Pharma Limited	4.62%	3.82%	16.29%	0.02%
	Chandra Bhagat Pharma Limited	0.73%	2.99%	3.29%	5.42%
	<b>Industry Avg:</b> Pharmaceuticals	N.A.	N.A.	N.A.	N.A.
NAV	<b>Issuer:</b> Fabino Life Sciences Limited	10.86	19.54	19.59	19.80
	<b>Peer Group: *</b>				
	Earum Pharmaceuticals Limited	23.51	13.56	3.03	2.26
	Vaishali Pharma Limited	21.25	24.99	38.43	39.97
	Chandra Bhagat Pharma Limited	34.29	35.35	36.41	38.45
	<b>Industry Avg:</b> Pharmaceuticals	N.A.	N.A.	N.A.	N.A.

*Sources:*

- 1) *For Issuer Company – Prospectus and Annual Reports.*
- 2) *For Peer Group – Annual Reports of the respective Companies.*
- 3) *For Industry Average – Capital Market of the respective period.*

**14. Any other material information:**

<b>Date</b>	<b>Particulars</b>
May 24, 2022	Fabino Life Sciences Limited informed BSE about appointment of Sumit Malik as an Additional Director of the Company.
July 26, 2022	Fabino Life Sciences Limited informed BSE about shifting of Registered office of the Company from the State of Delhi to the State of Haryana
August 04, 2022	Fabino Life Sciences Limited informed BSE about resignation of Jeel Poshya from the post of Company Secretary and Compliance Officer with effect from August 04, 2022
August 11, 2022	Fabino Life Sciences Limited informed BSE about appointment of Aslam Mohammad as Company Secretary and Compliance Officer with effect from August 11, 2022
May 02, 2023	Fabino Life Sciences Limited informed BSE about resignation of CS Aslam Mohammed as Company Secretary and Compliance Officer of the Company Fabino Life Sciences Limited informed BSE about appointment of CS Kanchi Gehlot as Company Secretary and Compliance Officer of the Company w.e.f. May 02, 2023.
July 29, 2023	Fabino Life Sciences Limited informed BSE about new Registered Office of the Company is Jeevan Vihar Extension, Near Shubham Garden, Murthal Road, Sonapat, Haryana-131001 with effect from July 25, 2022,
December 26, 2023	Fabino Life Sciences Limited informed BSE about acceptance of the resignation of Mr. Atul Kumar Jain (Managing Director) (DIN: 00004339) of the Company with effect from 26th December, 2023 Fabino Life Sciences Limited informed BSE about change in Designation of Mr. Aditya Mahavir Jain (DIN: 09353344) from Non - Executive Director to Managing Director of the Company.
April 02, 2024	Fabino Life Sciences Limited informed BSE about Alteration of Name Clause and Object Clause of Memorandum of Association ( MOA' ).
June 19, 2024	Fabino Life Sciences Limited informed BSE about Company's name has been changed from "Fabino Life Sciences Limited" to "Fabino Enterprises Limited" w.e.f. June 18, 2024.
August 22, 2024	Fabino Enterprises Limited informed BSE about Appointment of Jitendra Kumar as Additional Executive Director and Resignation of Satendra Kumar Jain from post of Executive Director.
August 22, 2024	Fabino Enterprises Limited informed BSE about Resignation of Gagan Gupta Non- Executive Independent Director vide letter dated August 22, 2024.

For details regarding material developments w.r.t the company, please refer to the "Notices" and "Announcements" on [www.bseindia.com](http://www.bseindia.com). The Scrip Code of the Company is 543444.

**General note: Terms capitalized herein which have not been defined have the same meaning as assigned to such terms in the Prospectus dated December 27, 2021.**

**All information above is updated till September 30, 2024 unless indicated otherwise.**

**Disclaimer**

This document is uploaded by Aryaman Financial Services Limited ("AFSL") on its website pursuant to the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012, without having regard to specific objectives, suitability, financial situations and needs of any particular person and does not constitute any recommendation, and should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities mentioned therein, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. Nothing in these materials is intended by AFSL to be construed as legal, accounting or tax advice. Past performance is not a guide for future performance. Neither AFSL nor its affiliates, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of this document. The information contained in this document is based on the Prospectus and amendments thereto, if any, and/or the Final Prospectus, as amended, if any, as applicable, of the Issuer ("Offer Documents") and the information as provided by the Issuer to AFSL and available with or provided by the Stock Exchanges / Regulators / Monitoring Agencies from time to time. AFSL reserves the right to make amendments to this document as and when it deems necessary and also to make additions or deletions to the information contained herein from time to time. In this context, the Issuer" would mean an issuer who has come out with the public issue of its securities as indicated in this document for the respective issues, whose information is being accessed by any person, in this document. The Directors of the Issuer have confirmed in the relevant Offer Documents that the information made available therein is true, fair, correct and adequate. AFSL has made efforts to ensure that the information is gathered from authentic sources, however, no representation or warranty, expressed or implied, is made or given by or on behalf of AFSL or its affiliates, nor any person who controls it or any director, officer, employee, advisor or agent of it, or affiliate of any such person or such persons as to the accuracy, authenticity, correctness, completeness or fairness of the information contained in this document and AFSL or its affiliates or such persons do not accept any responsibility or liability for any such information and therefore, any liability or responsibility is expressly disclaimed. This document has not been approved and will

or may not be reviewed or approved by any statutory or regulatory authority in India or by any Stock Exchange in India. This document may not be all inclusive and may not contain all of the information that the recipient may consider material. Since neither this document nor any copy of it may be taken or transmitted or distributed or re-distributed into certain jurisdictions, directly or indirectly, which may be restricted by law, persons into whose possession this document comes should inform them about, and observe, any such restrictions. Neither AFSL, nor any of its affiliates nor their respective directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you may incur in the event of any failure or disruption of this website, or resulting from the act or omission of any party involved in producing or hosting this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access or use of the website or these materials. This document is issued by AFSL without any liability / undertaking / commitment on the part of itself or AFSL or any other entity in the AFSL Group, except where it is explicitly stated. Further, in case of any commitment on behalf of AFSL or any other entity in the AFSL Group, such commitment is valid only when separately confirmed by that entity.

